A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Public ClinicalTrials.gov record NCT03498716. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer
Study identification
- NCT ID
- NCT03498716
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 2,199 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Cyclophosphamide Drug
- Dose-dense Doxorubicin or dose-dense Epirubicin Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2018
- Primary completion
- Aug 13, 2023
- Completion
- Aug 13, 2023
- Last update posted
- Aug 20, 2024
2018 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| John Muir Health Clinical Research Center | Concord | California | 94520 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Martin-O?Neil Cancer Center | St. Helena | California | 94574 | — |
| Baptist - MD Anderson Cancer Center | Jacksonville | Florida | 32207 | — |
| Advocate Illinois Masonic Outpatient Center for Advanced Care | Chicago | Illinois | 60657 | — |
| Des Moines Oncology Research Association | Des Moines | Iowa | 50309 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214-3728 | — |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Fairview Southdale Medical Oncology Clinic | Edina | Minnesota | 55435 | — |
| HCA Midwest Division | Kansas City | Missouri | 64132 | — |
| New Hampshire Hematology Oncology | Manchester | New Hampshire | 03103 | — |
| Monter Cancer Center | Lake Success | New York | 11042 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 11101 | — |
| Rochester General Hospital; Lipson Cancer and Blood Center | Rochester | New York | 14621 | — |
| SCRI | Nashville | Tennessee | 37203 | — |
| Intermountain Precision Genomics Cancer Research Clinic-Dixie | St. George | Utah | 84770 | — |
| St. Mary's Medical Center | Huntington | West Virginia | 25702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 347 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03498716, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2024 · Synced May 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03498716 live on ClinicalTrials.gov.